Charles River Laboratories International
 
 
 
 
公司概覽
業務類別 Diagnostics & Research
業務概覽 Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
公司地址 251 Ballardvale Street, Wilmington, MA, USA, 01887
電話號碼 +1 781 222-6000
傳真號碼 --
公司網頁 https://www.criver.com
員工數量 19700
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Glenn G. Coleman, C.P.A. Corporate Executive Vice President and Chief Financial Officer -- 18/02/2026
Mr. Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer 美元 448.12K 18/02/2026
Ms. Victoria L. Creamer Corporate Executive Vice President 美元 553.75K 18/02/2026
Ms. Birgit Girshick Chief Executive Officer and Director 美元 760.96K 09/01/2026
Mr. Joseph W. LaPlume Corporate Executive Vice President, Corporate Development and Strategy 美元 570.17K 18/02/2026
Ms. Shannon M. Parisotto Corporate Executive Vice President -- 18/02/2026
Mr. Mark Mintz Corporate Executive Vice President and Chief Information Officer & Global Shared Services -- 18/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. James C. Foster Director 09/01/2026
Dr. Martin W. Mackay, PhD Chairman of the Board 09/01/2026
Dr. Craig B. Thompson,M.D. Independent Director 31/03/2026
Ms. Virginia M. Wilson Independent Director 31/03/2026
Mr. Paul W. Graves Independent Director 31/03/2026
Mr. Mark Joseph Enyedy Independent Director 31/03/2026
Dr. Nancy C. Andrews, M.D.,PhD Independent Director 31/03/2026
Ms. Birgit Girshick Chief Executive Officer and Director 09/01/2026
Mr. George Llado, Sr Independent Director 31/03/2026
Mr. Steven K. Barg Independent Director 31/03/2026
Ms. Reshema Kemps-Polanco Independent Director 31/03/2026
Mr. Abraham Ceesay Director 31/03/2026
 
所屬ETF (更新日期: 14/11/2026 02:35)
代號 名稱 佔比% ▼ 持有日期
QVMLInvesco S&P 500 QVM Multi-factor ETF0.003%30/10/2026
QDPLPacer Metaurus US Lg Cp Dvd Mltp 400 ETF0.003%30/10/2026
EFIVState Street SPDR S&P500 Scrd&ScrndETF0.003%30/10/2026
HIBLDirexion Daily S&P 500® Hi Bt Bl 3X ETF0.002%31/10/2026
TAXCambria Tax Aware ETF0.002%30/10/2026
DSPYTema S&P 500 Hist Wght ETF Strat0.002%30/10/2026
CUREDirexion Daily Healthcare Bull 3X ETF0.002%31/10/2026
AAEQAlpha Architect US Equity 2 ETF0.002%30/10/2026
PSEPInnovator US Equity Power Buffer ETF-Sep0.002%30/10/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.002%30/10/2026
AAUSAlpha Architect US Equity ETF0.002%30/10/2026
XVViShares ESG Select Screened S&P 500 ETF0.002%30/10/2026
POCTInnovator U.S. Equity Power Buf ETF™ Oct0.002%30/10/2026
VLUState Street® SPDR® S&P® 1500 ValTiltETF0.002%30/10/2026
ISPYProShares S&P 500 High Income ETF0.001%30/10/2026
EPSBHarbor SMID Cap Core ETF0.001%31/10/2026
BMEDiShares Health Innovation Active ETF0.001%30/10/2026
BRSMMFS Blended Research Small-Mid Cap ETF0.001%30/10/2026
AAUAAlpha Architect US Equity 3 ETF0.001%30/10/2026
ZALTInnovator U.S. Equity 10 Buffr ETF - Qt0.001%30/10/2026
  1    2    3    4    5    6   7    8    9    10    11    12  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.